linagliptin
Brand: Tradjenta
Prototype: sitagliptin
Drug Class: DPP-4 inhibitor
Drug Family: antidiabetic
Subclass: dipeptidyl peptidase-4 inhibitor (hepatically cleared)
Organ Systems: endocrine
Mechanism of Action
Selective DPP-4 inhibitor; unique among DPP-4 inhibitors in that it is primarily eliminated non-renally (enterohepatic route), making it the only DPP-4 inhibitor requiring NO dose adjustment in any level of renal impairment.
DPP-4 enzyme
Indications
- type 2 diabetes mellitus
Contraindications
- type 1 diabetes
- DKA
Adverse Effects
Common
- nasopharyngitis
- upper respiratory infections
- diarrhea
Serious
- pancreatitis
- bullous pemphigoid
- severe arthralgia
- hypersensitivity
Pharmacokinetics (ADME)
| Absorption | oral bioavailability ~30% |
| Distribution | extensively distributed; >99% protein bound |
| Metabolism | minimal CYP3A4; primarily enterohepatic recirculation and fecal elimination unchanged |
| Excretion | fecal (~90% primarily unchanged); minimal renal excretion |
| Half-life | 12 hours (effective); terminal half-life up to 130 hours due to tight DPP-4 binding |
| Onset | rapid |
| Peak | 1.5 hours |
| Duration | 24 hours |
| Protein Binding | >99% (concentration-dependent) |
| Vd | 1110 L |
Drug Interactions
| Drug / Agent | Mechanism | Severity |
|---|---|---|
| strong CYP3A4/P-gp inducers (rifampin) | reduces linagliptin exposure by 40%; consider alternative DPP-4i | moderate |
Nursing Considerations
- Unique advantage: NO dose adjustment required for any level of renal impairment, including dialysis — especially useful in CKD patients where other DPP-4 inhibitors require dosage modification.
- 5 mg once-daily dose regardless of renal function; simplifies prescribing in complex patients.
- Monitor for bullous pemphigoid (skin blisters); FDA issued a safety communication; refer to dermatology if suspected.
- Educate patients that linagliptin has a favorable weight profile (weight-neutral) and low hypoglycemia risk.
Clinical Pearls
- Linagliptin's non-renal elimination pathway makes it uniquely appropriate for patients with advanced CKD (including dialysis), where all other DPP-4 inhibitors would require dose reduction.
- The CARMELINA trial demonstrated CV and renal safety without CV benefit or harm, making linagliptin safe but without the added cardiorenal protection offered by GLP-1 agonists or SGLT-2 inhibitors.
Safety Profile
Pregnancy insufficient-data
Lactation insufficient-data
Renal Adjustment Not required
Hepatic Adjustment Not required
TDM Not required
Concordance Terms
Cross-referenced clinical concepts — click any term to see all content where it appears.